1374598-80-7

Basic information

• Product Name: TAK875
• Synonyms: [(3S)-6-({2',6'-dimethyl-4'-[3-(methylsulfonyl)propoxy]biphe-nyl-3-yl}meth-oxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid hemi-hydrate;TAK875 (3S)-6-[[2',6'-Dimethyl-4'-[3-(methylsulfonyl)propoxy][1,1'-biphenyl]-3-yl]methoxy]-2,3-dihydro-3-benzofuranacetic acid;TAK-875(0.5H2O);(3S)-6-[[2',6'-Dimethyl-4'-[3-(methylsulfonyl)propoxy][1,1'-biphenyl]-3-yl]methoxy]-2,3-dihydro-3-benzofuranacetic acid hydrate (2:1);TAK875 hemihydrate
• CAS NO: 1374598-80-7
• Molecular Formula: C58H66O15S2
• Molecular Weight: 1067.26564
• Product Categories: Inhibitors;API
• Mol File: 1374598-80-7.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• CAS DataBase Reference: TAK875(CAS DataBase Reference)
• NIST Chemistry Reference: TAK875(1374598-80-7)
• EPA Substance Registry System: TAK875(1374598-80-7)

Safety Data

• Hazardous Substances Data: 1374598-80-7(Hazardous Substances Data)

Usage

General Description

TAK-875, also known as fasiglifam, is a chemical compound that acts as a selective GPR40 agonist. It is an investigational drug being developed for the treatment of type 2 diabetes. TAK-875 works by increasing glucose-stimulated insulin secretion while reducing hepatic glucose production, leading to improved glycemic control. It has shown promising results in clinical trials, demonstrating superior efficacy and tolerability compared to existing diabetes medications. However, its development was halted due to concerns about potential liver toxicity, despite its promising therapeutic effects. TAK-875 may still hold potential as a treatment for diabetes if safety concerns can be addressed.